Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma

Clinical trial NCT06946407 · RECRUITING

Trial details

NCT number: NCT06946407
Sponsor: FengYan Jin
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma (PCNSL)CNS Lymphoma Treatment

Start date: 2022-12-02
Primary completion: 2027-12-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.